mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma

por Bailey, Sean T., Zhou, Bing, Damrauer, Jeffrey S., Krishnan, Bhavani, Wilson, Harper L., Smith, Aleisha M., Li, Mingqing, Yeh, Jen Jen, Kim, William Y.
Publicado 2014

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma

por Bailey, Sean T., Smith, Aleisha M., Kardos, Jordan, Wobker, Sara E., Wilson, Harper L., Krishnan, Bhavani, Saito, Ryoichi, Lee, Hyo Jin, Zhang, Jing, Eaton, Samuel C., Williams, Lindsay A., Manocha, Ujjawal, Peters, Dorien J., Pan, Xinchao, Carroll, Thomas J., Felsher, Dean W., Walter, Vonn, Zhang, Qing, Parker, Joel S., Yeh, Jen Jen, Moffitt, Richard A., Leung, Janet Y., Kim, William Y.
Publicado 2017